Tag: CureVac

CureVac investors have officially cleared the path for the company's acquisition by vaccine developer BioNTech, bringing months of anticipation to ...

CureVac is preparing to conclude its journey as an independent entity, but not before delivering a significant financial surprise. As ...

The future of Tübingen-based biotech firm CureVac hangs in the balance as the company approaches a critical juncture. With operational ...

The countdown has begun for CureVac's final days as an independent publicly traded company. A special shareholder meeting scheduled for ...

Shareholders of the Tübingen-based biotech firm CureVac are approaching a decisive moment. An extraordinary general meeting scheduled for Tuesday, November ...

The future of CureVac as an independent entity now rests in shareholders' hands as a decisive vote approaches. Investors will ...

The independent existence of CureVac could soon be a chapter in corporate history. On November 25, shareholders will convene in ...

The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could ...

The acquisition drama surrounding German biopharmaceutical firm CureVac approaches its climax as investors prepare for a landmark shareholder vote. With ...

The proposed multi-billion euro acquisition of CureVac by BioNTech enters its final phase with two crucial November deadlines approaching. Shareholders ...